Search Results - "Butler, Javed"

Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.

Authors: Narula, Jagat Butler, Javed Chothia, Mogamat-Yazied et al.

Source: Indian Journal of Nephrology. Jan/Feb2026, Vol. 36 Issue 1, p1-26. 26p.

Continuous risk monitoring and management of heart failure: Rationale and design of the ALLEVIATE‐HF trial.

Authors: Butler, Javed Kahwash, Rami Khan, Muhammad Shahzeb et al.

Source: European Journal of Heart Failure. Apr2025, Vol. 27 Issue 4, p697-706. 10p.

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial.

Authors: Kahwash, Rami Butler, Javed Khan, Muhammad Shahzeb et al.

Source: Journal of the American College of Cardiology (JACC). Jun2026, Vol. 87 Issue 25, p3611-3628. 18p.

Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial.

Authors: Butler, Javed Kahwash, Rami Khan, Muhammad Shahzeb et al.

Source: Journal of the American College of Cardiology (JACC). Jun2026, Vol. 87 Issue 25, p3592-3607. 16p.

Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways.

Authors: Butler, Javed Khan, Muhammad Shahzeb Ferreira, João Pedro et al.

Source: Journal of the American College of Cardiology (JACC). Apr2026, Vol. 87 Issue 15, p1907-1935. 29p.

Biomarkers for Cardiovascular Drug Development: JACC State-of-the-Art Review.

Authors: Aimo, Alberto Butler, Javed De Michieli, Laura et al.

Source: Journal of the American College of Cardiology (JACC). Apr2026, Vol. 87 Issue 15, p1950-1972. 23p.

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.

Authors: Reddy, Yogesh N.V. Butler, Javed Anstrom, Kevin J. et al.

Source: European Journal of Heart Failure. Feb2025, Vol. 27 Issue 2, p209-218. 10p.

The win ratio for trials for heart failure: Academic desperation or investigator decadence?

Authors: Packer, Milton Butler, Javed

Source: European Journal of Heart Failure. Apr2025, Vol. 27 Issue 4, p620-622. 3p.

Role of anti‐obesity drugs in heart failure regardless of ejection fraction.

Authors: Butler, Javed Arshad, Muhammad Sameer Khan, Muhammad Shahzeb

Source: European Journal of Heart Failure. Aug2024, Vol. 26 Issue 8, p1703-1706. 4p.

Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial.

Authors: Sattar, Naveed Butler, Javed Lee, Matthew M.Y. et al.

Source: European Journal of Heart Failure. Apr2024, Vol. 26 Issue 4, p900-909. 10p.

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.

Authors: Mentz, Robert J. Butler, Javed McMullan, Ciaran J. et al.

Source: European Journal of Heart Failure. Dec2025, Vol. 27 Issue 12, p2825-2836. 12p.

Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?

Authors: Packer, Milton Butler, Javed Lam, Carolyn S.P. et al.

Source: Journal of the American College of Cardiology (JACC). Nov2025, Vol. 86 Issue 20, p1935-1949. 15p.

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐Reduced.

Authors: Böhm, Michael Butler, Javed Abdin, Amr et al.

Source: European Journal of Heart Failure. Nov2025, Vol. 27 Issue 11, p2218-2228. 11p.

Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials.

Authors: Ferreira, João Pedro Butler, Javed Anker, Stefan D. et al.

Source: European Journal of Heart Failure. Feb2024, Vol. 26 Issue 2, p274-284. 11p.

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors: Butler, Javed McMullan, Ciaran J Anstrom, Kevin J et al.

Source: Lancet. 9/27/2025, Vol. 406 Issue 10510, p1341-1350. 10p.

Residual risk in heart failure and the need for simultaneous implementation and innovation.

Authors: Fatima, Kaneez Butler, Javed Fonarow, Gregg C.

Source: European Journal of Heart Failure. Sep2023, Vol. 25 Issue 9, p1477-1480. 4p. 2 Graphs.

Implementation of sodium–glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be.

Authors: Pierce, Jacob B. Butler, Javed Greene, Stephen J.

Source: European Journal of Heart Failure. Sep2023, Vol. 25 Issue 9, p1659-1662. 4p. 1 Graph.

Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.

Authors: Packer, Milton Butler, Javed

Source: European Journal of Heart Failure. Sep2023, Vol. 25 Issue 9, p1537-1543. 7p. 1 Chart, 1 Graph.

Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial.

Authors: Böhm, Michael Butler, Javed Krawczyk, Marcin et al.

Source: European Journal of Heart Failure. Aug2023, Vol. 25 Issue 8, p1375-1383. 9p. 7 Graphs.

Potential global impact of sodium–glucose cotransporter‐2 inhibitors in heart failure.

Authors: Talha, Khawaja M. Butler, Javed Greene, Stephen J. et al.

Source: European Journal of Heart Failure. Jul2023, Vol. 25 Issue 7, p999-1009. 11p. 1 Diagram, 5 Charts.